There is no single life expectancy for pulmonary hypertension. The term encompasses very different diseases, and prognosis may vary substantially from person to person. The cause, severity at diagnosis, ability of the right ventricle to adapt to increased pulmonary resistance, age, other medical conditions and, above all, response to treatment are important.
For this reason, a figure found online cannot predict how long an individual patient will live.
Even within pulmonary arterial hypertension there are major differences. A low-risk person with good right ventricular function and a favorable response to treatment has a very different outlook from someone with advanced disease, syncope, right heart failure or impaired hemodynamic parameters.
The main points to understand are:
The condition known as pulmonary hypertension is a hemodynamic disorder that may arise from five major groups of diseases. Forms associated with left heart disease, lung conditions, chronic thromboembolism and PAH have different natural histories and treatment options. Subtypes within the same group may also affect risk.
Idiopathic PAH, PAH associated with systemic sclerosis and PAH associated with congenital heart disease, for example, do not necessarily follow the same course.
Prognosis also changes over time. The risk estimated at diagnosis is not a definitive verdict: it may improve if treatment reduces symptoms, increases exercise capacity, normalizes biomarkers and improves right ventricular function. Conversely, it may worsen if disease progresses or signs of right heart failure appear.
One of the most important factors is right ventricular function. The right ventricle must work against increasing resistance in the pulmonary circulation. As long as it can adapt, cardiac output may be maintained; when compensation fails, the risk of heart failure and clinical events increases.
For this reason, echocardiography, cardiac magnetic resonance imaging and hemodynamic assessment are used not just to measure pressure but also to understand how the right heart tolerates the load.
Other prognostic factors include functional class, which reflects how much symptoms limit everyday activities, the distance covered in the 6-minute walk test and BNP or NT-proBNP levels. Right atrial pressure, cardiac index, mixed venous oxygen saturation, size and function of the right heart chambers, any pericardial effusion and other clinical and instrumental parameters are also important.
No single measurement, including pulmonary arterial pressure, should therefore be interpreted in isolation.
The cause also matters. PAH associated with connective tissue diseases, particularly systemic sclerosis, may follow a different course from the idiopathic form. In CTEPH, by contrast, the possibility of correcting the obstructive component through pulmonary endarterectomy or angioplasty can profoundly change the clinical outlook.
For PAH, guidelines use a multiparametric risk assessment. At diagnosis, several variables are considered to classify patients into low-, intermediate- or high-risk categories. During follow-up, a more detailed four-stratum classification is also used: low, intermediate-low, intermediate-high and high risk.
The parameters most commonly used at follow-up include WHO functional class, the 6-minute walk test and BNP or NT-proBNP, supplemented by imaging and hemodynamic assessment when necessary.
The aim is not solely to predict events. Risk stratification helps guide treatment. If a patient remains in an intermediate- or high-risk category despite treatment, this may indicate the need to intensify therapy, add medications, consider parenteral prostacyclins or, in appropriate cases, initiate an evaluation for lung transplantation.
The September 2026 ERS update recommends sotatercept as add-on therapy in patients already receiving treatment who remain at intermediate-low, intermediate-high or high risk, and suggests repeat right heart catheterization during follow-up in these categories when it could change treatment decisions. Achieving and maintaining a low-risk profile is therefore a concrete treatment goal.
Registries have documented improved survival in PAH compared with the era before specific treatments became available. REVEAL data collected in the United States between 2006 and 2009 reported survival from diagnosis for the entire PAH cohort of 85% at 1 year, 68% at 3 years, 57% at 5 years and 49% at 7 years. These figures describe a population treated during a period predating many current strategies and must not be used as individual predictions.
A more recent US registry, the Pulmonary Hypertension Association Registry, which enrolled patients from 2015 to 2020, reported overall mortality of 8% at 1 year, 16% at 2 years and 21% at 3 years. Even there, risk varied enormously across categories: patients classified as low risk had much better outcomes than those at intermediate or high risk.
Furthermore, these data predate the current use of some newer treatments, including the new activin/BMP pathway, and cannot automatically be extrapolated to someone diagnosed today.
The useful conclusion is therefore not that "life expectancy is X years", but that prognosis depends strongly on the risk profile and response to treatment. The 7th World Symposium update also confirms that survival in PAH has improved, although the disease remains potentially serious.
An accurate and sufficiently early diagnosis allows treatment to begin before the right ventricle becomes severely impaired. In modern PAH management, initial combination therapy and intensification when treatment goals are not met have become central elements of the strategy. Studies and registries also show that an improved risk category during follow-up is associated with better outcomes.
It is therefore important not to rely on occasional check-ups. Patients should undergo regular reassessment of symptoms, functional capacity, biomarkers and cardiac function. Worsening dyspnea, syncope, a rapid decline in exercise capacity, increasing edema or signs of right heart failure require prompt assessment.
For patients who remain at high risk despite optimal therapy, early evaluation for lung transplantation may be part of care, avoiding delay until a terminal stage when options become more limited.
How long can someone live with pulmonary hypertension?
There is no figure that applies to everyone. Prognosis depends on the type of pulmonary hypertension, severity, right ventricular function, other coexisting diseases and response to treatment.
Is pulmonary arterial hypertension always fatal within a few years?
No. Historical data do not reflect the current situation. Survival has improved with earlier diagnosis, combination therapies and new treatments, but PAH remains a serious disease, and prognosis varies greatly among patients.
What is the most important prognostic factor?
The ability of the right ventricle to adapt to its workload is central. However, prognosis is assessed using several parameters together, including symptoms, functional class, walk test, BNP or NT-proBNP, imaging and hemodynamics.
Can treatment improve prognosis?
Yes. Moving into a lower-risk category during follow-up is associated with a better prognosis. Treatment is therefore reassessed and intensified when targets are not achieved.
Does a high pulmonary pressure value alone determine life expectancy?
No. Pressure is only one part of the overall picture. Right ventricular function, cardiac output, exercise capacity, biomarkers, disease cause and response to treatment all have important prognostic value.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.